Victoria Socha

DocwireNews

Tadao Akizawa, MD, and colleagues reported results of a post hoc analysis of data from a Japanese open-label, partially randomized, phase 3 study in patients with non-dialysis dependent chronic kidney disease (NDD-CKD). The study was designed to examine disease state-related parameters among patients with and without diabetes mellitus who received roxadustat. Results were reported online in Clinical and Experimental Nephrology [<a href="https://link.springer.com/article/10.1007/s10157-022-02225-w">doi.org/10.1007/s10157-022-022250w</a>].Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase for the treatment of anemia of CKD. In the 1517-CL-0310 study (NCT02988973), roxadustat was noninferior to darbepoetin alfa for change in average hemoglobin levels at weeks 18 to 24 from baseline. The post hoc analysis included patients enrolled in the study who received roxadustat.The researchers descriptively summarized parameters by visit through week 52. The parameters were: hematologic (hemoglobin, reticulocyte/erythrocyte ratio, mean corpuscular volume [MCV] and mean corpuscular hemoglobin [MCH]); iron-related (ferritin, total iron-binding capacity, transferrin, ceruloplasmin, and hepcidin); metabolic (hemoglobin A1c [HbA1c], glycated albumin, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol); and renal (estimated glomerular filtration rate).Of the 201 patients in the analysis, 552.% (n=105) were in the diabetes subgroup and 47.8% (n=96) were in the no diabetes subgroup. There were no clinically meaningful differences through week 52 between the two subgroups for most of the hematologic, iron-related, metabolic, or renal parameters. In patients in the diabetes subgroup, MCV and MCH remained lower and HbA1c and glycated albumin remained higher through week 52.In both subgroups, patients experienced a similar benefit from roxadustat in maintaining hemoglobin levels in the target range of 10 to 12 g/dL.In summary, the researchers said, &ldquo;Roxadustat maintained hemoglobin levels in the target range with similar clinical parameters irrespective of diabetes mellitus presence at baseline.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Clinical Parameters in Patients with CKD-related Anemia Treated with Roxadustat

Chronic Kidney Disease

Tadao Akizawa, MD, and colleagues reported results of a post hoc analysis of data from a Japanese open-label, partially randomized, phase 3 study in patients with non-dialysis ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe